Discover 1,438 paid clinical trials in Tacoma, Washington. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,438
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
for
Locally Advanced Urothelial Carcinoma,
Location: Seattle WA, Bellevue WA, Kirkland WA, Post Falls ID,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06524544
Phase3, Recruiting
Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance
for
IgA Monoclonal Gammopathy of Undetermined Significance,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center
Sex: All
Age: 18+
Code: NCT07209371
Phase2, Recruiting
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
for
Solid Tumours
Location: Seattle WA, West Valley City UT, Los Angeles CA,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT07160725
Phase1, Phase2, Recruiting
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
for
Locally Advanced Adrenal Cortical Carcinoma,
Location: Seattle WA, Madera CA, Aurora CO, La Jolla CA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 12+
Code: NCT06900595
Phase2, Recruiting
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
Get alerts for new trials in your area by subscribing now
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
for
Prostate Cancer (Adenocarcinoma),
Location: Seattle WA, Duarte CA, La Jolla CA, Minneapolis MN,
Sponsor: Prostate Cancer Clinical Trials Consortium
Sex: Male
Age: 18+
Code: NCT06844383
Phase2, Recruiting
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
for
Castration-Resistant Prostatic Cancer, Metastasis
Location: Seattle WA, Vancouver, San Francisco CA, Los Angeles CA,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06863272
Phase1, Phase2, Recruiting
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
for
Small Cell Lung Carcinoma,
Location: Seattle WA, Iowa City IA, Royal Oak MI, Montreal,
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT07006727
Phase1, Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
for
Progressive Metastatic Castrate Resistant Prostate Cancer
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
for
Advanced Or Metastatic Merkel Cell Carcinoma
Location: Seattle WA, San Francisco CA, Stanford CA,
Sponsor: TuHURA Biosciences, Inc.
Sex: All
Age: 18+
Code: NCT06947928
Phase2, Phase3, Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
for
Locally Advanced Cervical Adenocarcinoma,
Location: Seattle WA, Vancouver WA, Portland OR, Clackamas OR,
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT07061977
Phase3, Recruiting
Influencing Next-Generation Oncologic Outcomes Through Rapid Integration of Functional Precision Medicine (NOORI): A Feasibility Study of SmartMatch in Rare Gynecologic Cancers
for
Malignant Female Reproductive System Neoplasm,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center
Sex: Female
Age: 18+
Code: NCT07731880
Recruiting
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
for
Muscle Invasive Bladder Carcinoma,
Location: Seattle WA
Sponsor: University of Washington
Sex: All
Age: 18+
Code: NCT07579195
Phase1, Phase2, Recruiting
Interpersonal Communication Training and Vaccination Workflow Training Alone and in Combination to Improve Communication and Recommendations About HPV Vaccination in Pharmacies, IMPACT HPV Trial
for
Human Papillomavirus-Related Carcinoma
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center
Sex: All
Age: 18+
Code: NCT06926062
Recruiting
Patient Navigation and the Planning Advance Care Together Website to Improve Goals of Care Conversations in Hematopoietic Cell Transplant Survivors, IMPACT-HCT Trial
for
Hematopoietic and Lymphatic System Neoplasm
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center
Sex: All
Age: 18+
Code: NCT07052630
Recruiting
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
for
Solid Tumor Malignancies
Location: Seattle WA, Salt Lake City UT, Los Angeles CA,
Sponsor: Kumquat Biosciences Inc.
Sex: All
Age: 18+
Code: NCT07207707
Phase1, Recruiting
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia
for
Acute Myeloid Leukemia
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center
Sex: All
Age: 18+
Code: NCT07645469
Phase1, Recruiting
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
for
Hematopoietic and Lymphatic System Neoplasm, Autoimmune Disease,
Location: Seattle WA, Duarte CA, Houston TX
Sponsor: Fred Hutchinson Cancer Center
Sex: All
Age: 18+
Code: NCT06817889
Phase2, Recruiting
Selinexor and Backbone Treatments of Multiple Myeloma Patients
for
Multiple Myeloma
Location: Seattle WA, Durham NC, Boston MA
Sponsor: Karyopharm Therapeutics Inc
Sex: All
Age: 18+
Code: NCT02343042
Phase1, Phase2, Recruiting
A Multilevel Intervention to Increase Colorectal Cancer Screening Tests in Patients With Abnormal Fecal Immunochemical Test Results, PROACT Trial